FDA to review whether to allow more access to certain peptides

medicalxpress - The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.

AI Summary: The FDA is moving toward expanding access to certain compounded peptides, opening a regulatory review that could loosen limits on how pharmacies and clinics obtain and prepare these popular therapies. The review balances potential patient demand and shortages against safety and quality-control concerns, putting compounding practices squarely under the spotlight.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months

FDA refuses to review Moderna mRNA flu vaccine application / 3 months

FDA rejects Atara cell therapy for Epstein–Barr virus complications / 4 months

FDA clears first Alzheimer’s blood test as capillary sampling research advances biomarker access / 3 months

FDA to Remove Black Box Warnings from Menopausal Hormone Therapies / 6 months